NanoViricides, Inc. (NASDAQ:NNVC) |

• NanoViricides, Inc. filed its annual report detailing the Phase II clinical trials for NV-387, a broad-spectrum antiviral drug. • The company is targeting unmet medical needs for MPox and Ebola, noting that no approved drugs currently exist for the treatment of MPox Clade I or Clade II.

• Senators questioned FDA nominee Heidi Overton during a hearing regarding her positions on vaccines, vapes, and abortion. • Overton frequently avoided giving direct answers to the senators' questions during the session.

• Three top U.S. federal health officials will join over 900 rare disease leaders at the 2026 NORD Rare Diseases and Orphan Products Breakthrough Summit from October 25–27 in Washington, D.C. • Attendees will include Kyle Diamantas, the Acting Commissioner of Food and Drugs at the U.S. Food and Drug Administration.

• The European Commission adopted a proposal on Monday for a Council recommendation to combat cardiovascular diseases. • These heart-related conditions are the leading cause of death in Europe, claiming 1.7 million lives annually.

• A phase 3 clinical trial found that delivering focused radiation therapy over three to five sessions after brain metastasis surgery reduced cancer recurrence compared to a single session. • This study represents the first randomized trial to directly compare these two specific radiation delivery schedules.

• The Pan American Health Organization (PAHO) marked the 50th anniversary of its Health Emergencies Program on September 28, 2026. • Regional coordination mechanisms were activated within hours to support national and international responses after two powerful earthquakes struck Venezuela in June 2026.

• Experts at the University Medical City's Second Annual Scientific Research Day discussed how artificial intelligence can accelerate medical research and improve healthcare decision-making. • The participants highlighted that AI technology can support more precise treatment for patients.

• The Centers for Disease Control and Prevention updated its online immunization guidance in late September 2026 to recommend COVID-19 vaccinations for specific groups. • The agency now recommends the vaccine for all adults 18 and older and for children aged 6 months to 17 years who are moderately to severely immunocompromised.

• Dr. Jarbas Barbosa, Director of the Pan American Health Organization (PAHO), called for accelerated action on emerging health challenges during the opening of the 63rd Directing Council. • The Director identified primary health care, vaccination, digital health, and emergency preparedness as the region's top priorities.

• The FDA approved the once-daily pill Baricitinib for adolescents aged 12 and older suffering from severe alopecia areata, a condition causing patchy hair loss. • A large trial found a new type of eye drug performed as well as standard anti-VEGF therapy for treating diabetic macular edema, which affects 1.6 million Americans.

• Nearly 600 postmarket studies for FDA-approved drugs and biologics are currently behind their scheduled completion dates. • These delayed studies are required safety and efficacy evaluations that the FDA mandates after a medicine is already available for sale.